AT Semicon-Woong Bio Tech to Advance FDA Clinical Trials for Virus Therapeutics with the Korean Society of Clinical Health Sciences

[Asia Economy Reporter Jang Hyowon] As the government prepares for With Corona (living with COVID-19), AT Semicon is moving forward with the commercialization of a virus treatment.

On the 15th, AT Semicon announced that Woong Biotech signed a joint business agreement with the Korean Society of Clinical Health to develop and commercialize new antimicrobial and antiviral drugs using the virus eradication candidate substance ‘Now-St’.

Now-St, developed with proprietary technology by Woong Biotech, is a virus eradication candidate substance. Last year, it obtained FDA (U.S. Food and Drug Administration) Phase 1 clinical trial approval, demonstrating 99.9% eradication of E. coli, Staphylococcus, Salmonella, and Pseudomonas aeruginosa. The Now-St manufacturing device also received disinfection and sterilization certification after confirming 95.6% eradication of Severe Acute Respiratory Syndrome (SARS).

Additionally, the substance has completed safety verification for humans in clinical trials. The company explained that it is not only the first case in Korea but also a rare example worldwide for a disinfectant and sterilization product that kills bacteria and viruses to be certified as harmless to humans.

According to the agreement, AT Semicon and Woong Biotech plan to accelerate FDA clinical trials along with the commercialization of the Now-St substance in cooperation with the Korean Society of Clinical Health. Furthermore, AT Semicon expects to reduce production costs by utilizing its idle semiconductor cleanroom facilities as production sites for virus eradication products.

The Korean Society of Clinical Health is a domestic non-profit public interest society that collaborates with the U.S. FDA laboratory. It supports approximately 2,000 domestic companies by assisting with FDA registration and certified clinical trial research for COVID-19 prevention supplies such as masks, medical devices, pharmaceuticals, cosmetics, food, and K-quarantine products.

A company official stated, “We expect to gain momentum in clinical certification of the Now-St substance through cooperation with the Korean Society of Clinical Health, which has played a unique role in FDA certification in Korea,” adding, “Starting from this agreement, we will expand the R&D pipeline of the Now-St substance to create new momentum.”